RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: Comparison with RECIST 1.0

American Journal of Roentgenology

Volumn 201, Issue 1, 2013, Pages

  Nishino, Mizuki ^a,b   Cardarella, Stephanie ^b   Jackman, David M ^b   Ramaiya, Nikhil H ^a,b   Rabin, Michael S ^b   Hatabu, Hiroto ^b   Jänne, Pasi A ^b   Johnson, Bruce E ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); Lung cancer; Non small cell lung cancer (NSCLC); Response Evaluation Criteria in Solid Tumors (RECIST); Tumor response assessment; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER SIZE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG RESPONSE; EGFR GENE; EXON; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECIST 1.0; RECIST 1.1; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84883396112     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9668     Document Type: Article

References (39)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
3. Nishino M, Jagannathan JP, Ramaiya N, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR 2010; 195:281-289
4. Nishino M, Jackman DM, Hatabu H, et al. New Response Evaluation Criteria in Solid Tumors (revised RECIST guideline, version 1.1) in advanced non-small-cell lung cancer: comparison with the original RECIST (version 1.0) and its impact on assessment of tumor response to therapy. AJR 2010; 195:[web]W221W228
5. Zhao B, James LP, Moskowitz CS, et al. Evaluating variability in tumor measurements from sameday repeat CT scans of patients with non-small cell lung cancer. Radiology 2009; 252:263-272
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29
7. American Cancer Society website. Cancer facts and figures, 2000 www.cancer.org/acs/groups/content/@ epidemiologysurveilance/documents/document/ acspc-031941.pdf. Accessed March 6, 2013
8. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009; 361:1018-1020
9. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-1703
10. Nishino M, Jackman DM, Hatabu H, Johnson BE, Van den Abbeele AD. Imaging of lung cancer in the era of molecular medicine. Acad Radiol 2011; 18:424-436
11. Nishino M, Guo M, Jackman DM, et al. CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of emerging clinical tool. Acad Radiol 2011; 18:54-62
12. van Zandwijk N, Mathy A, Boerrigter L, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro-and prospective observations in non-small-cell lung cancer. Ann Oncol 2007; 18:99-103
13. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26:2442-2449
14. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in nonsmall cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:3908-3914
15. Mok TS, Wu YL, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957
16. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-2388
17. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735-742
18. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239-246
19. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73
20. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043
21. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786-792
22. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 23:75ra26
23. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acidbased assay. Clin Cancer Res 2011; 17:1169-1180
24. Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010; 16:5873-5882
25. Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012; 18:4406-4414
26. Jackman DM, Cioffredi LA, Lindeman N, et al. Phase II trial of erlotinib in chemotherapy-naïve women with advanced pulmonary adenocarcinoma. J Clin Oncol 2009;27(suppl, abstr 8065):15s
27. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients ≤ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760-766
28. Jänne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004; 44:221-230
29. Jänne PA, Wang XF, Socinski MA, et al. Randomized phase III trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 304 J Clin Oncol 2010; 28(suppl; abstr 7503):15s
30. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
31. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500
32. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-smallcell lung cancer. J Clin Oncol 2010; 28:357-360
33. Kundel HL, Polansky M. Measurement of observer agreement. Radiology 2003; 228:303-308
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
35. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367-1380
36. Sun JM, Ahn MJ, Park MJ, et al. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer 2010; 69:105-109
37. Piatek CI, Desai BB, Wei-Tsao D, et al. RECIST 1.0 versus 1.1: implications for trial interpretation and design in advanced prostate cancer. J Clin Oncol 2011; 29(suppl, abstr 2563)
38. Zacharia TT, Saini S, Halpern EF, Sumner JE. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure. AJR 2006; 186:1067-1070
39. Nishino M, Jagannathan JP, Krajewski KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR 2012; 198:737-745